E

    Embecta Corp (EMBC)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $5.14
    +0.09 (+1.78%)

    Market Cap: $286.13M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    94%(16/17)
    Avg Surprise
    +43.76%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.48
    Range$0.47 - $0.50
    4 analysts
    Revenue Consensus
    $276M
    Range$275M - $277M
    4 analysts
    Dec 31, 2026
    EPS Consensus$0.49
    Range$0.39 - $0.67
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$0.49-0.7%
    60d ago$0.48-2.7%
    30d ago$0.48-2.7%
    7d ago$0.48-2.7%
    Current$0.49
    Revenue Consensus
    $268M
    Range$265M - $274M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.49---
    Sep 26EST
    		-$0.48---
    Jun 26
    		$0.56$0.26+115.38%Beat-50.0%
    Mar 26
    		$0.27$0.42-35.71%Miss-61.4%
    Dec 25
    		$0.71$0.67+5.97%Beat+9.2%
    Sep 25
    		$0.50$0.46+8.70%Beat+11.1%
    Jun 25
    		$1.12$0.78+43.59%Beat+51.4%
    Mar 25
    		$0.70$0.59+18.64%Beat+4.5%
    Dec 24
    		$0.65$0.44+47.73%Beat+6.6%
    Sep 24
    		$0.45$0.36+25.00%Beat-23.7%
    Jun 24
    		$0.74$0.46+60.87%Beat+7.2%
    Mar 24
    		$0.67$0.40+67.50%Beat-10.7%
    Dec 23
    		$0.61$0.46+32.61%Beat-36.5%
    Sep 23
    		$0.59$0.40+47.50%Beat-50.0%
    Jun 23
    		$0.69$0.46+50.00%Beat-43.0%
    Mar 23
    		$0.75$0.48+56.25%Beat-45.7%
    Dec 22
    		$0.96$0.52+84.62%Beat-86.6%
    Sep 22
    		$1.18$0.67+76.12%Beat-
    Jun 22
    		$1.21$0.87+39.08%Beat-
    Mar 22
    		$1.38N/AN/ABeat-
    Dec 21
    		$7.17$0.00N/ABeat-

    Dividends

    Dividend Metrics

    Yield6.23%
    Annual/Share$0.32
    Payout Ratio20.72%
    Frequency4
    Pay MonthsMar, Jun, Sep, Dec
    View EMBC's full dividend history

    Key Metrics

    Valuation
    P/E Ratio2.52EV/EBITDA5.84x
    Price/FCF1.77xFCF Yield56.52%
    Profitability
    Profit Margin8.59%Operating Margin23.70%
    ROE0.00%ROIC18.42%
    Financial Health
    Debt/Equity-2.37xInterest Coverage2.25x
    Current Ratio1.68xQuick Ratio1.17x
    Trading Statistics
    Beta0.79Avg Volume1.78M
    52-Week High$15.0552-Week Low$2.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.13
    SMA 20$4.82
    SMA 50$3.92
    SMA 200$7.78
    EMA 10$5.02
    EMA 20$4.78
    EMA 50$4.43
    EMA 200$6.91

    MACD

    Line: 0.35Signal: 0.39Hist: -0.04

    ADX

    ADX: 37.0+DI: 29.5-DI: 17.2

    Aroon & PSAR

    Aroon Up72.0
    Aroon DownN/A
    PSAR$5.47

    Bollinger Bands

    Upper Band$5.95
    Lower Band$3.69
    %B Position4679%(Upper)
    Band Width0.64

    RSI (14-Day)

    Neutral
    64.8

    Momentum Oscillators

    Stoch %K49.2
    Stoch %D54.3
    Williams %R-48.7
    ROC (10d)0.4%
    Momentum0.02
    CCI (20d)46.2
    MFI (14d)67.9

    Volatility Measures

    ATR (14d)$0.28(5.4%)
    StdDev (20d)0.56
    Hist Vol115.2%(High)

    Volume Flow

    VWAP$5.10
    OBV-5.1M
    AD Line-312.7M
    CMF (20d)0.093

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio1.5x(High)
    VWMA (20d)$4.83

    Pivot Points

    R3$5.35
    R2$5.26
    R1$5.16
    Pivot Point$5.07
    S1$4.97
    S2$4.88
    S3$4.78

    Advanced Oscillators

    TSI33.27
    Ultimate Osc49.6
    KST452.11

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$271.70M$221.80M$261.20M$264.00M$295.50M$259.00M$261.90M$286.10M$272.50M$287.20M$277.30M$281.90M
    Cost of Revenue$118.40M$94.00M$99.50M$105.50M$98.40M$94.90M$104.80M$112.30M$82.40M$101.80M$91.40M$100.10M
    Gross Profit$153.30M$127.80M$161.70M$158.50M$197.10M$164.10M$157.10M$173.80M$190.10M$185.40M$185.90M$181.80M
    Operating Expenses$104.60M$92.80M$78.40M$102.00M$103.10M$101.20M$128.40M$147.60M$134.20M$146.20M$140.40M$156.00M
    R&D$5.60M$5.40M$4.60M$4.60M$4.40M$8.00M$20.30M$19.80M$20.40M$18.40M$20.20M$23.60M
    SG&A$78.60M$76.20M$77.60M$97.40M$84.40M$79.60M$81.10M$127.80M$113.80M$127.80M$120.20M$129.90M
    Operating Income$48.70M$35.00M$83.30M$56.50M$94.00M$62.90M$28.70M$26.20M$55.90M$39.20M$45.50M$25.80M
    Interest Income$-23,900,000$-22,600,000$-24,100,000$-26,100,000$-26,600,000$-26,700,000$-27,900,000$-29,000,000$-27,800,000$-27,800,000$-27,700,000$-27,600,000
    Interest Expense$21.10M$25.50M$24.40M$27.50M$21.80M$27.10M$29.40M$33.20M$28.90M$29.30M$31.20M$20.80M
    Income Before Tax$27.60M$9.50M$58.90M$29.00M$72.20M$35.80M$-700,000$-7,000,000$27.00M$9.90M$14.30M$5.00M
    Income Tax Expense$6.50M$13.60M$14.80M$2.60M$26.70M$12.30M$-700,000$-21,600,000$12.30M$-19,000,000$-5,800,000$-1,000,000
    Net Income$21.10M$-4,100,000$44.10M$26.40M$45.50M$23.50M$0$14.60M$14.70M$28.90M$20.10M$6.00M
    EBITDA$68.00M$46.80M$97.80M$73.40M$113.00M$76.20M$41.20M$36.10M$67.50M$49.50M$52.80M$43.50M
    EBIT$51.50M$32.10M$83.00M$55.10M$98.80M$62.50M$27.20M$22.00M$54.80M$37.70M$42.00M$32.60M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EMBC

    News

    Embecta: Excellent Turnaround Prospect In Defensive Medical Products

    Embecta (EMBC) presents a compelling deep-value opportunity in defensive medical products, trading at a P/E below 3x and a free cash flow yield over 50%. Despite some sales decline and high debt, its high gross margins and market leadership support a bullish 12-month target of $8-10 per share. Technical momentum, insider buying, and high short interest suggest a potential sharp rebound if fundamentals stabilize, with takeover potential adding to its appeal.

    Seeking Alpha•8/25/26•
    Bullish

    EMBC Deadline Alert: The Gross Law Firm Reminds Embecta Corp. (EMBC) Investors of Securities Class Action Deadline on August 17, 2026

    The Gross Law Firm has issued a notice reminding Embecta Corp. (NASDAQ: EMBC) investors of the securities class action deadline on August 17, 2026. The lawsuit alleges that Embecta made misleading statements about its fiscal results, particularly concerning its pen needle business, leading to a significant stock price drop after the company missed Q2 2026 guidance and lowered its full-year outlook. Shareholders who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact the firm regarding lead plaintiff appointment.

    Eastern Progress•8/22/26•
    Bearish

    EMBC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc

    Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Embecta Corp. (NASDAQ:EMBC) for alleged federal securities law violations. The lawsuit claims Embecta made materially false and misleading statements regarding its business and prospects, particularly concerning its pen needle business and fiscal guidance. Investors who suffered losses between November 25, 2025, and May 4, 2026, have an opportunity to lead the class action lawsuit, with a deadline of August 17, 2026, to request appointment as lead plaintiff.

    The National Law Review•8/22/26•
    Bearish

    Price to book forward of Embecta Corporation – HAM:JX7

    This article provides financial data for Embecta Corporation (HAM:JX7) on the Hamburg Stock Exchange, specifically focusing on its "Price to book forward" metric. The content highlights the stock's market status as closed with no trades and indicates that detailed financial information is available.

    TradingView•8/21/26•
    Neutral

    EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

    Bernstein Liebhard LLP is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The investigation aims to determine if the Company's leadership acted in the best interests of shareholders and if legal remedies are available. Shareholders who purchased shares before November 25, 2025, are encouraged to contact the firm for more information.

    TMX Newsfile•8/18/26•
    Bearish

    Frequently Asked Questions About EMBC

    What is EMBC's current dividend yield?
    Embecta Corp (EMBC) has a current dividend yield of 6.23%.
    Does EMBC pay dividends?
    Yes, Embecta Corp pays dividends with a current yield of 6.23%.
    What is EMBC's P/E ratio?
    Embecta Corp has a price-to-earnings (P/E) ratio of 2.52.
    What is EMBC's market cap?
    Embecta Corp (EMBC) has a market capitalization of $286.13M with a current stock price of $5.14.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In